Chapitre 10: Le traitement de la tuberculose active chez les populations particulières

Références

• Creswell J, Raviglione M, Ottmani S, et al. Tuberculosis and noncommunicable diseases: neglected links and missed opportunities. Eur Respir J. 2011;37(5):1269–1282. doi:10.1183/09031936.00084310.
   PubMed Web of Science ®Google Scholar
• Mathad JS, Gupta A. Tuberculosis in Pregnant and Postpartum Women: Epidemiology, Management, and Research Gaps. Clin Infect Dis. 2012;55(11):1532–49. doi:10.1093/cid/cis732.
   PubMed Web of Science ®Google Scholar
• Perumal R, Naidoo K, Naidoo A, et al. A systematic review and meta-analysis of first-line tuberculosis drug concentrations and treatment outcomes. Int J Tuberc Lung Dis. 2020;24(1):48–64. doi:10.5588/ijtld.19.0025.
   PubMed Web of Science ®Google Scholar
• Wood R, Maartens G, Lombard CJ. Risk Factors for Developing Tuberculosis in HIV-1-infected adults from communities with a low or very high incidence of tuberculosis. J Acquir Immune Defic Syndr. 2000;23(1):75–80. doi:10.1097/00126334-200001010-00010.
   PubMed Web of Science ®Google Scholar
• Selwyn PA, Hartel D, Lewis VA, et al. A Prospective Study of the Risk of Tuberculosis among Intravenous Drug Users with Human Immunodeficiency Virus Infection. N Engl J Med. 1989;320(9):545–550. doi:10.1056/nejm198903023200901.
   PubMed Web of Science ®Google Scholar
• Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. The Lancet. 1993;342(8866):268–272. doi:10.1016/0140-6736(93)91817-6.
   PubMed Web of Science ®Google Scholar
• Suthar AB, Lawn SD, del Amo J, et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med. 2012;9(7):e1001270. doi:10.1371/journal.pmed.1001270.
   PubMed Web of Science ®Google Scholar
• Gupta A, Wood R, Kaplan R, Bekker LG, Lawn SD. Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community. PLoS One. 2012;7(3):e34156–8. doi:10.1371/journal.pone.0034156.
   Web of Science ®Google Scholar
• Houben RMGJ, Crampin AC, Ndhlovu R, et al. Human immunodeficiency virus associated tuberculosis more often due to recent infection than reactivation of latent infection. International Journal of Tuberculosis and Lung Disease. 2011;15(1):24–31. doi:10.5588/ijtld.11.0115.
   PubMed Web of Science ®Google Scholar
• Oni T, Burke R, Tsekela R, et al. High prevalence of subclinical tuberculosis in HIV-1-infected persons without advanced immunodeficiency: implications for TB screening. Thorax. 2011;66(8):669–673. doi:10.1136/thx.2011.160168.
   PubMed Web of Science ®Google Scholar
• Aderaye G, Bruchfeld J, Assefa G, et al. The relationship between disease pattern and disease burden by chest radiography, M. tuberculosis load, and HIV status in patients with pulmonary tuberculosis in Addis Ababa. Infection. 2004;32(6):333–338. doi:10.1007/s15010-004-3089-x.
   PubMed Web of Science ®Google Scholar
• Li J, Munsiff SS, Driver CR, Sackoff J. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000. Clinical Infectious Diseases. 2005;41(1):83–91. doi:10.1086/430377.
   PubMed Web of Science ®Google Scholar
• Nettles RE, Mazo D, Alwood K, et al. Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. Clin Infect Dis. 2004;38(5):731–736. doi:10.1086/381675.
   PubMed Web of Science ®Google Scholar
• Comstock GW, Golub JE, Panjabi R. Recurrent tuberculosis and its risk factors: Adequately treated patients are still at high risk. International Journal of Tuberculosis and Lung Disease. 2007;11(8):828–837.
   PubMed Web of Science ®Google Scholar
• Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: A cohort study in South African mineworkers. Lancet. 2001;358(9294):1687–1693. doi:10.1016/S0140-6736(01)06712-5.
   PubMed Web of Science ®Google Scholar
• Ahmad Khan F, Minion J, Al-Motairi A, Benedetti A, Harries AD, Menzies D. An updated systematic review and meta-analysis on the treatment of active tuberculosis in patients with HIV infection. Clin Infect Dis. 2012;55(8):1154–1163. doi:10.1093/cid/cis630.
   PubMed Web of Science ®Google Scholar
• Haar CH, Cobelens FGJ, Kalisvaart NA, Van Gerven PJHJ, Van Der Have JJ. HIV-related mortality among tuberculosis patients in the Netherlands, 1993-2001. International Journal of Tuberculosis and Lung Disease. 2007;11(9):1038–1041.
   PubMed Web of Science ®Google Scholar
• El-Sadr WM, Perlman DC, Matts JP, et al. Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG). Clin Infect Dis. 1998;26(5):1148–1158. doi:10.1086/520275.
   PubMed Web of Science ®Google Scholar
• Perriëns JH, St. Louis ME, Mukadi YB, et al. Pulmonary Tuberculosis in HIV-Infected Patients in Zaire—A Controlled Trial of Treatment for Either 6 or 12 Months. N Engl J Med. 1995;332(12):779–785. doi:10.1056/NEJM199503233321204.
   PubMed Web of Science ®Google Scholar
• Davies G, Cerri S, Richeldi L. Rifabutin for treating pulmonary tuberculosis. The Cochrane Database of Systematic Reviews. 2005; (1):22–24. doi:10.1002/14651858.cd005159.
   Google Scholar
• Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016;63(7):e147–e195. doi:10.1093/cid/ciw376.
   PubMed Web of Science ®Google Scholar
• Bracchi M, van Halsema C, Post F, et al. British HIV Association guidelines for the management of tuberculosis in adults living with HIV 2019. HIV Med. 2019;20:s2–s83. doi:10.1111/hiv.12748.
   PubMed Web of Science ®Google Scholar
• Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-infected Adults and Adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. 2021. https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines. Consulté le 1er novembre 2021.
   Google Scholar
• Mfinanga SG, Kirenga BJ, Chanda DM, et al. Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): A prospective, international, randomised, placebo-controlled trial. Lancet Infect Dis. 2014;14(7):563–571. doi:10.1016/S1473-3099(14)70733-9.
   PubMed Web of Science ®Google Scholar
• Gopalan N, Santhanakrishnan RK, Palaniappan AN, et al. Daily vs intermittent antituberculosis therapy for pulmonary tuberculosis in patients with HIV: A Randomized Clinical Trial. JAMA Intern Med. 2018;178(4):485–493. doi:10.1001/jamaint-ernmed.2018.0141.
   PubMed Web of Science ®Google Scholar
• Tappero JW, Bradford WZ, Agerton TB, et al. Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. Clinical Infectious Diseases. 2005;41(4):461–469. doi:10.1086/431984.
   PubMed Web of Science ®Google Scholar
• Chideya S, Winston CA, Peloquin CA, et al. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis. 2009;48(12):1685–1694. doi:10.1086/599040.
   PubMed Web of Science ®Google Scholar
• Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: An update. Drugs. 2014;74(8):839–854. doi:10.1007/s40265-014-0222-8.
   PubMed Web of Science ®Google Scholar
• Babalik A, Babalik A, Mannix S, Francis D, Menzies D. Therapeutic drug monitoring in the treatment of active tuberculosis. Can Respir J. 2011;18(4):225–229. doi:10.1155/2011/307150.
   PubMed Web of Science ®Google Scholar
• Daskapan A, Idrus LR, Postma MJ, et al. A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs. Clin Pharmacokinet. 2019;58(6):747–766. doi:10.1007/s40262-018-0716-8.
   PubMed Web of Science ®Google Scholar
• Kwara A, Enimil A, Gillani FS, et al. Pharmacokinetics of first-line antituberculosis drugs using WHO revised dosage in children with tuberculosis with and without HIV coinfection. J Pediatric Infect Dis Soc. 2016;5(4):356–365. doi:10.1093/jpids/piv035.
   PubMed Web of Science ®Google Scholar
• Märtson AG, Burch G, Ghimire S, Alffenaar JWC, Peloquin CA. Therapeutic drug monitoring in patients with tuberculosis and concurrent medical problems. Expert Opin Drug Metab Toxicol. 2021;17(1):23–39. doi:10.1080/17425255.2021.1836158.
   PubMed Web of Science ®Google Scholar
• Sileshi T, Tadesse E, Makonnen E, Aklillu E. The impact of first-line anti-tubercular Drugs’ Pharmacokinetics on Treatment Outcome: A Systematic Review. Clin Pharmacol. 2021;13:1–12. doi:10.2147/CPAA.S289714.
   PubMed Web of Science ®Google Scholar
• Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis. 2013;208(9):1464–1473. doi:10.1093/infdis/jit352.
   PubMed Web of Science ®Google Scholar
• Weiner M, Benator D, Burman W, Tuberculosis Trials Consortium, et al. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis. 2005;40(10):1481–1491. doi:10.1086/429321.
   PubMed Web of Science ®Google Scholar
• Uthman OA, Okwundu C, Gbenga K, et al. Optimal timing of antiretroviral therapy initiation for HIV-infected adults with newly diagnosed pulmonary tuberculosis: A systematic review and meta-analysis. Ann Intern Med. 2015;163(1):32–39. doi:10.7326/M14-2979.
   PubMed Web of Science ®Google Scholar
• Burke RM, Rickman HM, Singh V, et al. What is the optimum time to start antiretroviral therapy in people with HIV and tuberculosis coinfection? A systematic review and meta‐analysis. J Int AIDS Soc. 2021;24(7):e25772. doi:10.1002/jia2.25772.
   PubMed Web of Science ®Google Scholar
• Organisation mondiale de la Santé. Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring: recommendations for a Public Health Approach. 2021. Genève, Suisse. https://www.who.int/publications/i/item/9789240031593. Consulté le 1er novembre 2021.
   Google Scholar
• Torok ME, Yen NT, Chau TT, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculous meningitis. Clin Infect Dis. 2011;52(11):1374–1383. doi:10.1093/cid/cir230.
   PubMed Web of Science ®Google Scholar
• Cerrone M, Alfarisi O, Neary M, et al. Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide. J Antimicrob Chemother. 2019;74(6):1670–1678. doi:10.1093/jac/dkz068.
   PubMed Web of Science ®Google Scholar
• De Castro N, Marcy O, Chazallon C, et al. Standard dose ral- tegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial. The Lancet Infectious Diseases. 2021;21(6):813–822. doi:10.1016/S1473-3099(20)30869-0.
   PubMed Web of Science ®Google Scholar
• Wenning LA, Hanley WD, Brainard DM, et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2009;53(7):2852–2856. doi:10.1128/AAC.01468-08.
   PubMed Web of Science ®Google Scholar
• Dooley KE, Kaplan R, Mwelase N , International Study of Patients with HIV on Rifampicin ING study group, et al. Dolutegravir-based Antiretroviral Therapy for Patients Coinfected with Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial. Clinical Infectious Diseases. 2019;70(4):549–556. doi:10.1093/cid/ciz256.
   Web of Science ®Google Scholar
• Wang X, Cerrone M, Ferretti F, et al. Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin. Int J Antimicrob Agents. 2019;54(2):202–206. doi:10.1016/j.ijantimicag.2019.04.009.
   PubMed Web of Science ®Google Scholar
• Dooley KE, Sayre P, Borland J, et al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: Results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr. 2013;62(1):21–27. doi:10.1097/QAI.0b013e318276cda9.
   PubMed Web of Science ®Google Scholar
• Manosuthi W, Kiertiburanakul S, Sungkanuparph S, et al. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 Weeks results. AIDS. 2006;20(1):131–132. doi:10.1097/01.aids.0000196181.18916.9b.
   PubMed Web of Science ®Google Scholar
• Meintjes G, Brust JCM, Nuttall J, Maartens G. Management of active tuberculosis in adults with HIV. Lancet Hiv. 2019;6(7):e463–e474. doi:10.1016/S2352-3018(19)30154-7.
   PubMed Web of Science ®Google Scholar
• Cohen K, Meintjes G. Management of individuals requiring an- tiretroviral therapy and TB treatment. Curr Opin HIV Aids. 2010;5(1):61–69. doi:10.1097/COH.0b013e3283339309.
   PubMed Web of Science ®Google Scholar
• Brainard DM, Kassahun K, Wenning LA, et al. Lack of a clinically meaningful pharmacokinetic effect of rifabutin on raltegravir: In vitro/in vivo correlation. J Clin Pharmacol. 2011;51(6):943–950. doi:10.1177/0091270010375959.
   PubMed Web of Science ®Google Scholar
• Meintjes G, Lawn SD, Scano F, International Network for the Study of HIV-associated IRIS, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis. 2008;8(8):516–523. doi:10.1016/S1473-3099(08)70184-1.
   PubMed Web of Science ®Google Scholar
• Marais S, Meintjes G, Pepper DJ, et al. Frequency, severity, and prediction of tuberculous meningitis immune reconstitution in- flammatory syndrome. Clin Infect Dis. 2013;56(3):450–460. doi:10.1093/cid/cis899.
   PubMed Web of Science ®Google Scholar
• Manabe YC, Breen R, Perti T, Girardi E, Sterling TR. Unmasked tuberculosis and tuberculosis immune reconstitution inflammatory disease: A disease spectrum after initiation of antiretroviral therapy. J Infect Dis. 2009;199(3):437–444. doi:10.1086/595985.
   PubMed Web of Science ®Google Scholar
• Meintjes G, Rangaka MX, Maartens G, et al. Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and antitubercular drug resistance. Clin Infect Dis. 2009;48(5):667–676. doi:10.1086/596764.
   PubMed Web of Science ®Google Scholar
• Meintjes G, Wilkinson RJ, Morroni C, et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS. 2010;24(15):2381–2390. doi:10.1097/QAD.0b013e32833dfc68.
   PubMed Web of Science ®Google Scholar
• Meintjes G, Stek C, Blumenthal L , PredART Trial Team, et al. Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS. N Engl J Med. 2018;379(20):1915–1925. doi:10.1056/nejmoa1800762.
   PubMed Web of Science ®Google Scholar
• Subramanian AK. Mycobacterium tuberculosis in Transplantation. Emerging Transplant Infections: Clinical Challenges and Implications. 2020;:1–16. doi:10.1007/978-3-030-01751-4_15-1.
   Google Scholar
• Torre-Cisneros J, Doblas A, Aguado JM , Spanish Network for Research in Infectious Diseases, et al. Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the resitra (spanish network of infection in transplantation) cohort. Clin Infect Dis. 2009;48(12):1657–1665. doi:10.1086/599035.
   PubMed Web of Science ®Google Scholar
• Benito N, García-Vázquez E, Horcajada JP, et al. Clinical features and outcomes of tuberculosis in transplant recipients as compared with the general population: A retrospective matched cohort study. Clinical Microbiology and Infection. 2015;21(7):651–658. doi:10.1016/j.cmi.2015.03.010.
   PubMed Web of Science ®Google Scholar
• Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: Impact and implications for management. Clin Infect Dis. 1998;27(5):1266–1277. doi:10.1086/514993.
   PubMed Web of Science ®Google Scholar
• Subramanian AK, Theodoropoulos NM. Mycobacterium tuberculosis infections in solid organ transplantation: Guidelines from the infectious diseases community of practice of the American Society of Transplantation. Clin Transplant. 2019;33(9):e13513. doi:10.1111/ctr.13513.
   PubMed Web of Science ®Google Scholar
• Giacomelli IL, Neto RS, Marchiori E, Pereira M, Hochhegger B. Chest x-ray and chest ct findings in patients diagnosed with pulmonary tuberculosis following solid organ transplantation: A systematic review. J Bras Pneumol. 2018;44(2):161–166. doi:10.1590/s1806-37562017000000459.
   PubMed Web of Science ®Google Scholar
• Muñoz P, Rodríguez C, Bouza E. Mycobacterium tuberculosis infection in recipients of solid organ transplants. Clin Infect Dis. 2005;40(4):581–587. doi:10.1086/427692.
   PubMed Web of Science ®Google Scholar
• Abad CLR, Razonable RR. Mycobacterium tuberculosis after solid organ transplantation: A review of more than 2000 cases. Clin Transplant. 2018;32(6):e13259. doi:10.1111/ctr.13259.
   PubMed Web of Science ®Google Scholar
• Sun HY, Munoz P, Torre-Cisneros J, et al. Tuberculosis in solid-organ transplant recipients: Disease characteristics and outcomes in the current era. Prog Transplant. 2014;24(1):37–43. doi:10.7182/pit2014398.
   PubMed Web of Science ®Google Scholar
• Aguado J, Torre-Cisneros J, Fortun J, et al. Tuberculosis in solid-organ transplant recipients: Consensus statement of the Group for the Study of Infection in transplant recipients (GESITRA) of the Spanish society of infectious diseases and clinical microbiology. Clin Infect Dis. 2009;48(9):1276–1284. doi:10.1086/597590.
   PubMed Web of Science ®Google Scholar
• Meije Y, Piersimoni C, Torre-Cisneros J, Dilektasli AG, Aguado JM. Mycobacterial infections in solid organ transplant recipients. Clinical Microbiology and Infection. 2014;20:89–101. doi:10.1111/1469-0691.12641.
   PubMed Web of Science ®Google Scholar
• Pennington KM, Kennedy CC, Chandra S, et al. Management and diagnosis of tuberculosis in solid organ transplant candidates and recipients: Expert survey and updated review. J Clin Tuberc Other Mycobact Dis. 2018;11:37–46. doi:10.1016/j.jc-tube.2018.04.001.
   PubMedGoogle Scholar
• Baciewicz AM, Chrisman CR, Finch CK, Self TH. Update on rifampin, rifabutin, and rifapentine drug interactions. Curr Med Res Opin. 2013;29(1):1–12. doi:10.1185/03007995.2012.747952.
   PubMed Web of Science ®Google Scholar
• Hickey MD, Quan DJ, Chin-Hong PV, Roberts JP. Use of rifabutin for the treatment of a latent tuberculosis infection in a patient after solid organ transplantation. Liver Transpl. 2013;19(4):457–461. doi:10.1002/lt.23622.
   PubMed Web of Science ®Google Scholar
• López-Montes A, Gallego E, López E, et al. Treatment of tuberculosis with rifabutin in a renal transplant recipient. American Journal of Kidney Diseases. 2004;44(4):e59–63.doi:10.1053/j.ajkd.2004.06.015.
   PubMed Web of Science ®Google Scholar
• Grassi C, Peona V. Use of rifabutin in the treatment of pulmonary tuberculosis. Clinical Infectious Diseases. 1996;22(Supplement_1):S50–S54. doi:10.1093/clinids/22.supple-ment_1.s50.
   PubMedGoogle Scholar
• Mcgregor MM, Olliaro P, Wolmarans L, et al. Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. Am J Respir Crit Care Med. 1996;154(5):1462–1467. doi:10.1164/ajrccm.154.5.8912765.
   PubMed Web of Science ®Google Scholar
• Crabol Y, Catherinot E, Veziris N, Jullien V, Lortholary O. Rifabutin: Where do we stand in 2016? J Antimicrob Chemother. 2016;71(7):1759–1771. doi:10.1093/jac/dkw024.
   PubMed Web of Science ®Google Scholar
• Sun HY, Munoz P, Torre-Cisneros J, et al. Mycobacterium tuberculosis-associated immune reconstitution syndrome in solid-organ transplant recipients. Transplantation. 2013;95(9):1173–1181. doi:10.1097/TP.0b013e31828719c8.
   PubMed Web of Science ®Google Scholar
• Park YS, Choi JY, Cho CH, et al. Clinical outcomes of tuberculosis in renal transplant recipients. Yonsei Med J. 2004;45(5):865–872. doi:10.3349/ymj.2004.45.5.865.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Fan W, Yang G, et al. Risk of tuberculosis in patients treated with TNF-α antagonists: A systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2017;7(3):e012567–8. doi:10.1136/bmjopen-2016-012567.
   Web of Science ®Google Scholar
• Sartori NS, de Andrade NPB, da Silva Chakr RM. Incidence of tuberculosis in patients receiving anti-TNF therapy for rheumatic diseases: a systematic review. Clin Rheumatol. 2020;39(5):1439–1447. doi:10.1007/s10067-019-04866-x.
   PubMed Web of Science ®Google Scholar
• Dobler CC. Biological agents and tuberculosis: Risk estimates and screening strategies. Int J Rheum Dis. 2015;18(3):264–267. doi:10.1111/1756-185X.12672.
   PubMed Web of Science ®Google Scholar
• Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V , BIOBADASER Group, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. 2005;52(6):1766–1772. doi:10.1002/art.21043.
   PubMed Web of Science ®Google Scholar
• Lorenzetti R, Zullo A, Ridola L, et al. Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: A systematic review of randomized controlled trials. Ann Med. 2014;46(7):547–554. doi:10.3109/07853890.2014.941919.
   PubMed Web of Science ®Google Scholar
• Dixon WG, Hyrich KL, Watson KD, BSR Biologics Register, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis. 2010;69(3):522–528. doi:10.1136/ard.2009.118935.
   PubMed Web of Science ®Google Scholar
• Singh JA, Wells GA, Christensen R, Cochrane Musculoskeletal Group, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. The Cochrane Database of Systematic Reviews. 2011;81(2):CD008794. doi:10.1002/14651858.CD008794.pub2.
   Google Scholar
• Gómez-Reino JJ, Carmona L, Rodríguez Valverde V, Mola EM, Montero MD , BIOBADASER Group Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report. Arthritis Rheum. 2003;48(8):2122–2127. doi:10.1002/art.11137.
   PubMed Web of Science ®Google Scholar
• Ai JW, Zhang S, Ruan QL, et al. The risk of tuberculosis in patients with rheumatoid arthritis treated with tumor necrosis factor-α antagonist: A metaanalysis of both randomized controlled trials and registry/cohort studies. J Rheumatol. 2015;42(12):2229–2237. doi:10.3899/jrheum.150057.
   PubMed Web of Science ®Google Scholar
• Solovic I, Sester M, Gomez-Reino JJ, Series "update on tuberculosis". edited by C. Lange, M. Raviglione, W.W. Yew and G.B, et al. Migliori number 2 in this series: The risk of tuberculosis related to tumour necrosis factor antagonist therapies: A TBNET consensus statement. Eur Respir J. 2010;36(5):1185–1206. doi:10.1183/09031936.00028510.
   PubMed Web of Science ®Google Scholar
• Arend SM, Leyten EMS, Franken WPJ, Huisman EM, Van Dissel JT. A patient with de novo tuberculosis during anti-tumor necrosis factor-alpha therapy illustrating diagnostic pitfalls and paradoxical response to treatment. Clin Infect Dis. 2007;45(11):1470–1475. doi:10.1086/522993.
   PubMed Web of Science ®Google Scholar
• Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clinical Infectious Diseases. 2004;38(9):1261–1265. doi:10.1086/383317.
   PubMed Web of Science ®Google Scholar
• Mohan AK, Coté TR, Block JA, Manadan AM, Siegel JN, Braun MM. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis. 2004;39(3):295–299. doi:10.1086/421494.
   PubMed Web of Science ®Google Scholar
• Godfrey MS, Friedman LN. Tuberculosis and Biologic Therapies: Anti-Tumor Necrosis Factor-α and Beyond. Clin Chest Med. 2019;40(4):721–739. Version française disponible à l’adresse suivante: https://www.canada.ca/content/dam/phac-aspc/migration/phac-aspc/publicat/ccdr-rmtc/17vol43/dr-rm43-3-4/assets/pdf/17vol43_3_4-ar-04-fra.pdf. doi:10.1016/j.ccm.2019.07.003.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Tuberculosis associated with blocking agents against tumor necrosis factor-alpha–California, 2002-2003. MMWR Recommendations and Reports: Morbidity and Mortality Weekly Report Recommendations and Reports/Centers for Disease Control. 2004;53(30):683–685. doi:10.1001/jama.292.14.1676.
   PubMedGoogle Scholar
• Cantini F, Prignano F, Goletti D. Restarting biologics and management of patients with flares of inflammatory rheumatic disorders or psoriasis during active tuberculosis treatment. J Rheumatol Suppl. 2014;91(0):78–82. doi:10.3899/jrheum.140106.
   PubMedGoogle Scholar
• Wallis RS, van Vuuren C, Potgieter S. Adalimumab treatment of life-threatening tuberculosis. Clin Infect Dis. 2009;48(10):1429–1432. doi:10.1086/598504.
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Tanaka T, Kawase I. Infliximab for Rheumatoid Arthritis in a Patient with Tuberculosis. N Engl J Med. 2006;355(7):740–741. doi:10.1056/nejmc053468.
   PubMed Web of Science ®Google Scholar
• Garcia Vidal C, Rodríguez Fernández S, Martínez Lacasa J, et al. Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis. 2005;40(5):756–759. doi:10.1086/427941.
   PubMed Web of Science ®Google Scholar
• Dobler CC. Biologic Agents and Tuberculosis. Microbiol Spectr. 2016;4(6). doi:10.1128/microbiolspec.TNMI7-0026-2016.
   PubMed Web of Science ®Google Scholar
• Hsu DC, Faldetta KF, Pei L, et al. A Paradoxical Treatment for a Paradoxical Condition: Infliximab Use in Three Cases of Mycobacterial IRIS. Clin Infect Dis. 2016;62(2):258–261. doi:10.1093/cid/civ841.
   PubMed Web of Science ®Google Scholar
• Cho SK, Kim D, Won S, et al. Safety of resuming biologic DMARDs in patients who develop tuberculosis after anti-TNF treatment. Semin Arthritis Rheum. 2017;47(1):102–107. doi:10.1016/j.semarthrit.2017.01.004.
   PubMed Web of Science ®Google Scholar
• Kim HW, Kwon SR, Jung KH, Korean Society of Spondyloarthritis Research, et al. Safety of resuming tumor necrosis factor inhibitors in ankylosing spondylitis patients concomitant with the treatment of active tuberculosis: A retrospective nationwide registry of the Korean Society of spondyloarthritis research. PLoS One. 2016;11(4):e0153816–14. doi:10.1371/journal.pone.0153816.
   Web of Science ®Google Scholar
• Kim YJ, Kim YG, Shim TS, et al. Safety of resuming tumour necrosis factor inhibitors in patients who developed tuberculosis as a complication of previous TNF inhibitors. Rheumatology (Oxford). 2014;53(8):1477–1481. doi:10.1093/rheumatology/keu041.
   PubMed Web of Science ®Google Scholar
• Ozguler Y, Hatemi G, Ugurlu S, et al. Re-initiation of biologics after the development of tuberculosis under anti-TNF therapy. Rheumatol Int. 2016;36(12):1719–1725. doi:10.1007/s00296-016-3575-3.
   PubMed Web of Science ®Google Scholar
• Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: A systematic review of 13 observational studies. PLoS Med. 2008;5(7):e152–1101. doi:10.1371/journal.pmed.0050152.
   Web of Science ®Google Scholar
• Al-Rifai RH, Pearson F, Critchley JA, Abu-Raddad LJ. Association between diabetes mellitus and active tuberculosis: A systematic review and meta-analysis. PLoS One. 2017;12(11):e0187967–26. doi:10.1371/journal.pone.0187967.
   Web of Science ®Google Scholar
• Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis. 2009;9(12):737–746. doi:10.1016/S1473-3099(09)70282-8.
   PubMed Web of Science ®Google Scholar
• Viney K, Mills T, Harley D. Tuberculosis and diabetes mellitus: A dose-response relationship between the odds of tuberculosis and HbA1c. Int j Tuberc Lung Dis. 2019;23(10):1055–1059. doi:10.5588/ijtld.18.0657.
   PubMed Web of Science ®Google Scholar
• Golub JE, Mok Y, Hong S, Jung KJ, Jee SH, Samet JM. Diabetes mellitus and tuberculosis in Korean adults: Impact on tuberculosis incidence, recurrence and mortality. Int J Tuberc Lung Dis. 2019;23(4):507–513. doi:10.5588/ijtld.18.0103.
   PubMed Web of Science ®Google Scholar
• Leung CC, Yew WW, Mok TYW, et al. Effects of diabetes mellitus on the clinical presentation and treatment response in tuberculosis. Respirology. 2017;22(6):1225–1232. doi:10.1111/resp.13017.
   PubMed Web of Science ®Google Scholar
• Wang CS, Yang CJ, Chen HC, et al. Impact of type 2 diabetes on manifestations and treatment outcome of pulmonary tuberculosis. Epidemiol Infect. 2009;137(2):203–210. doi:10.1017/S0950268808000782.
   PubMed Web of Science ®Google Scholar
• Morris JT, Seaworth BJ, McAllister CK. Pulmonary tuberculosis in diabetics. Chest. 1992;102(2):539–541. doi:10.1378/chest.102.2.539.
   PubMed Web of Science ®Google Scholar
• Park SW, Shin JW, Kim JY, et al. The effect of diabetic control status on the clinical features of pulmonary tuberculosis. Eur J Clin Microbiol Infect Dis. 2012;31(7):1305–1310. doi:10.1007/s10096-011-1443-3.
   PubMed Web of Science ®Google Scholar
• Baker MA, Harries AD, Jeon CY, et al. The impact of diabetes on tuberculosis treatment outcomes: A systematic review. BMC Med. 2011;9(1):81. doi:10.1186/1741-7015-9-81.
   PubMed Web of Science ®Google Scholar
• Degner NR, Wang JY, Golub JE, Karakousis PC. Metformin Use Reverses the Increased Mortality Associated with Diabetes Mellitus during Tuberculosis Treatment. Clin Infect Dis. 2018;66(2):198–205. doi:10.1093/cid/cix819.
   PubMed Web of Science ®Google Scholar
• Huangfu P, Pearson F, Ugarte-Gil C, Critchley J. Diabetes and poor tuberculosis treatment outcomes: Issues and implications in data interpretation and analysis. Int J Tuberc Lung Dis. 2017;21(12):1214–1219. doi:10.5588/ijtld.17.0211.
   PubMed Web of Science ®Google Scholar
• Martinez L, Zhu L, Castellanos ME, et al. Glycemic Control and the Prevalence of Tuberculosis Infection: A Population-based Observational Study. Clin Infect Dis. 2017;65(12):2060–2068. doi:10.1093/cid/cix632.
   PubMed Web of Science ®Google Scholar
• Mave V, Gaikwad S, Barthwal M, et al. Diabetes Mellitus and Tuberculosis Treatment Outcomes in Pune, India. Open Forum Infect Dis. 2021;8(4):ofab097. doi:10.1093/ofid/ofab097.
   PubMed Web of Science ®Google Scholar
• Armstrong LR, Steve Kammerer J, Haddad MB. Diabetes mellitus among adults with tuberculosis in the USA, 2010-2017. BMJ Open Diabetes Research and Care. 2020;8(1):1–6. doi:10.1136/bmjdrc-2020-001275.
   Google Scholar
• Ugarte-Gil C, Alisjahbana B, Riza AL. Diabetes mellitus among pulmonary tuberculosis patients from four TB-endemic countries: the TANDEM study. Clin Infect Dis. 2020;70(5):780–788. doi:10.1093/cid/ciz284.
   PubMed Web of Science ®Google Scholar
• White LV, Edwards T, Lee N, et al. Patterns and predictors of co-morbidities in Tuberculosis: A cross-sectional study in the Philippines. Sci Rep. 2020;10(1):1–12. doi:10.1038/s41598-020-60942-2.
   PubMed Web of Science ®Google Scholar
• Workneh MH, Bjune GA, Yimer SA. Prevalence and associated factors of tuberculosis and diabetes mellitus comorbidity: A systematic review. PLoS One. 2017;12(4):e0175925–25. doi:10.1371/journal.pone.0175925.
   Web of Science ®Google Scholar
• Segafredo G, Kapur A, Robbiati C, et al. Integrating TB and non-communicable diseases services: Pilot experience of screening for diabetes and hypertension in patients with Tuberculosis in Luanda, Angola. PLoS One. 2019;14(7):e0218052–11. doi:10.1371/journal.pone.0218052.
   Web of Science ®Google Scholar
• Barss L, Sabur N, Orlikow E, et al. Diabetes Mellitus in adult patients with active tuberculosis in Canada: Presentation and treatment outcomes. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine. 2019;3(2):84–90. doi:10.1080/24745332.2018.1507615.
   Web of Science ®Google Scholar
• Grint D, Alisjhabana B, Ugarte-Gil C , TANDEM consortium, et al. Accuracy of diabetes screening methods used for people with tuberculosis, Indonesia, Peru, Romania, South Africa. Bull World Health Organ. 2018;96(11):738–749. doi:10.2471/BLT.17.206227.
   PubMed Web of Science ®Google Scholar
• Lin Y, Harries AD, Kumar AMV, et al. Management of Diabetes Mellitus-Tuberculosis. International Union against Tuberculosis and Lung Disease. 2019. https://theunion.org/sites/default/files/2020-11/TheUnion_DMTB_Guide.pdf. Consulté le 1er novembre 2021.
   Google Scholar
• Huangfu P, Ugarte-Gil C, Golub J, Pearson F, Critchley J. The effects of diabetes on tuberculosis treatment outcomes: an updated systematic review and meta-analysis. Int J Tuberc Lung Dis. 2019;23(7):783–796. doi:10.5588/ijtld.18.0433.
   PubMed Web of Science ®Google Scholar
• Kornfeld H, Singhal A. Enlisting the Host to Fight TB. Chest. 2018;153(6):1292–1293. doi:10.1016/j.chest.2018.01.011.
   PubMed Web of Science ®Google Scholar
• Shewade HD, Jeyashree K, Mahajan P, et al. Effect of glycemic control and type of diabetes treatment on unsuccessful TB treatment outcomes among people with TB-Diabetes: A systematic review. PLoS One. 2017;12(10):e0186697–17. doi:10.1371/journal.pone.0186697.
   Web of Science ®Google Scholar
• Yu X, Li L, Xia L, et al. Impact of metformin on the risk and treatment outcomes of tuberculosis in diabetics: A systematic review. BMC Infect Dis. 2019;19(1):859. doi:10.1186/s12879-019-4548-4.
   PubMed Web of Science ®Google Scholar
• Mtabho CM, Semvua HH, Van Den Boogaard J, et al. Effect of diabetes mellitus on TB drug concentrations in Tanzanian patients. J Antimicrob Chemother. 2019;74(12):3537–3545. doi:10.1093/jac/dkz368.
   PubMed Web of Science ®Google Scholar
• Alfarisi O, Mave V, Gaikwad S, et al. Effect of diabetes mellitus on the pharmacokinetics and pharmacodynamics of tuberculosis treatment. Antimicrob Agents Chemother. 2018;62(11):1–14. doi:10.1128/AAC.01383-18.
   Web of Science ®Google Scholar
• Dekkers BGJ, Akkerman OW, Alffenaar JWC. Role of therapeutic drug monitoring in treatment optimization in tuberculosis and diabetes mellitus comorbidity. Antimicrob Agents Chemother. 2019;63(2):1–7. doi:10.1128/AAC.02074-18.
   Web of Science ®Google Scholar
• Alkabab Y, Keller S, Dodge D, Houpt E, Staley D, Heysell S. Early interventions for diabetes related tuberculosis associate with hastened sputum microbiological clearance in Virginia, USA. BMC Infect Dis. 2017;17(1):1–8. doi:10.1186/s12879-017-2226-y.
   PubMedGoogle Scholar
• Pradhan RP, Katz LA, Nidus BD, Matalon R, Eisinger RP. Tuberculosis in dialyzed patients. JAMA. 1974;229(7):798–800. doi:10.1001/jama.1974.03230450032020.
   PubMed Web of Science ®Google Scholar
• Dobler CC, McDonald SP, Marks GB. Risk of tuberculosis in dialysis patients: A nationwide cohort study. PLoS One. 2011;6(12):e29563–6. doi:10.1371/journal.pone.0029563.
   Web of Science ®Google Scholar
• Park S, Lee S, Kim Y, et al. Association of CKD with incident tuberculosis. CJASN. 2019;14(7):1002–1010. doi:10.2215/CJN.14471218.
   PubMed Web of Science ®Google Scholar
• Cho PJY, Wu CY, Johnston J, Wu MY, Shu CC, Lin HH. Progression of chronic kidney disease and the risk of tuberculosis: An observational cohort study. Int J Tuberc Lung Dis. 2019;23(5):555–562. doi:10.5588/ijtld.18.0225.
   PubMed Web of Science ®Google Scholar
• Yan M, Puyat JH, Shulha HP, Clark EG, Levin A, Johnston JC. Risk of tuberculosis associated with chronic kidney disease: a population-based analysis. Nephrology Dialysis Transplantation. 2021;37(1):197–116. doi:10.1093/ndt/gfab222.
   PubMed Web of Science ®Google Scholar
• Romanowski K, Clark EG, Levin A, Cook VJ, Johnston JC. Tuberculosis and chronic kidney disease: an emerging global syndemic. Kidney Int. 2016;90(1):34–40. doi:10.1016/j.kint.2016.01.034.
   PubMed Web of Science ®Google Scholar
• Dalrymple LS, Katz R, Kestenbaum B, et al. The risk of infection-related hospitalization with decreased kidney function. American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation. 2012;59(3):356–363. doi:10.1053/j.ajkd.2011.07.012.
   PubMed Web of Science ®Google Scholar
• Milburn H, Ashman N, Davies P , British Thoracic Society Standards of Care C, Joint Tuberculosis C, et al. Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease. Thorax. 2010;65(6):557–570. doi:10.1136/thx.2009.133173.
   PubMed Web of Science ®Google Scholar
• Stamatakis G, Montes C, Trouvin JH, et al. Pyrazinamide and pyrazinoic acid pharmacokinetics in patients with chronic renal failure. Clin Nephrol. 1988;30(4):230–234.
   PubMed Web of Science ®Google Scholar
• Varughese A, Brater DC, Benet LZ, Lee CSC. Ethambutol kinetics in patients with impaired renal function. American Review of Respiratory Disease. 1986;134(1):34–38. doi:10.1016/0278-2316(86)90005-8.
   PubMedGoogle Scholar
• Ahn C, Oh KH, Kim K, et al. Effect of peritoneal dialysis on plasma and peritoneal fluid concentrations of isoniazid, pyrazinamide, and rifampin. Perit Dial Int. 2003;23(4):362–367. doi:10.1177/089686080302300409.
   PubMed Web of Science ®Google Scholar
• Si M, Li H, Chen Y, Peng H. Ethambutol and isoniazid induced severe neurotoxicity in a patient undergoing continuous ambulatory peritoneal dialysis. BMJ Case Reports. 2018;2018:bcr-2017-223187–5. doi:10.1136/bcr-2017-223187.
   PubMedGoogle Scholar
• Saukkonen JJ, Cohn DL, Jasmer RM, ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee, et al. An official ATS statement: Hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174(8):935–952. doi:10.1164/rccm.200510-1666ST.
   PubMed Web of Science ®Google Scholar
• Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of Serious Side Effects from First-Line Antituberculosis Drugs among Patients Treated for Active Tuberculosis. Am J Respir Crit Care Med. 2003;167(11):1472– doi:10.1164/rccm.200206-626OC.
   PubMed Web of Science ®Google Scholar
• Alshammari TM, Larrat EP, Morrill HJ, Caffrey AR, Quilliam BJ, LaPlante KL. Risk of hepatotoxicity associated with fluoro- quinolones: A national case-control safety study. Am J Health Syst Pharm. 2014;71(1):37–43. doi:10.2146/ajhp130165.
   PubMed Web of Science ®Google Scholar
• Paterson JM, Mamdani MM, Manno M, Juurlink DN , Canadian Drug Safety and Effectiveness Research Network Fluoroquinolone therapy and idiosyncratic acute liver injury: A population-based study. CMAJ. 2012;184(14):1565–1570. doi:10.1503/cmaj.111823.
   PubMed Web of Science ®Google Scholar
• Shah H, Bilodeau M, Burak KW, Canadian Association for the Study of the Liver, et al. The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver. CMAJ. 2018;190(22):E677–E687. doi:10.1503/cmaj.170453.
   PubMed Web of Science ®Google Scholar
• Coffin CS, Fung SK, Alvarez F, et al. Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of the Liver and Association of Medical Microbiology and Infectious Disease Canada. CanLivJ. 2018;1(4):156–217. doi:10.3138/canlivj.2018-0008.
   Google Scholar
• Chitnis AS, Cheung R, Gish RG, Wong RJ. Epidemiology and Prevention of Tuberculosis and Chronic Hepatitis B Virus Infection in the United States. J Immigrant Minority Health. 2021;23(6):1213–1267. doi:10.1007/s10903-021-01231-6.
   Web of Science ®Google Scholar
• Nooredinvand HA, Connell DW, Asgheddi M, et al. Viral hepatitis prevalence in patients with active and latent tuberculosis. World J Gastroenterol. 2015;21(29):8920–8980. doi:10.3748/wjg.v21.i29.8920.
   PubMed Web of Science ®Google Scholar
• Chua APG, Lim LKY, Gan SH, Chee CBE, Wang YT. The role of chronic viral hepatitis on tuberculosis treatment interruption. Int j Tuberc Lung Dis. 2018;22(12):1486–1494. doi:10.5588/ijtld.18.0195.
   PubMed Web of Science ®Google Scholar
• Chen L, Bao D, Gu L, et al. Co-infection with hepatitis B virus among tuberculosis patients is associated with poor outcomes during anti-tuberculosis treatment. BMC Infect Dis. 2018;18(1):1–10. doi:10.1186/s12879-018-3192-8.
   PubMedGoogle Scholar
• Kim WS, Lee SS, Lee CM, et al. Hepatitis C and not Hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injury. BMC Infect Dis. 2016;16(1):1–7. doi:10.1186/s12879-016-1344-2.
   PubMedGoogle Scholar
• Zheng J, Guo MH, Peng HW, Cai XL, Wu YL, Peng XE. The role of hepatitis B infection in anti-tuberculosis drug-induced liver injury: A meta-analysis of cohort studies. Epidemiol Infect. 2020;148:E290. doi:10.1017/S0950268820002861.
   PubMed Web of Science ®Google Scholar
• Ungo JR, Jones D, Ashkin D, et al. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med. 1998;157(6):1871–1876. doi:10.1164/ajrccm.157.6.9711039.
   PubMed Web of Science ®Google Scholar
• Lui GCY, Wong NS, Wong RYK, et al. Antiviral Therapy for Hepatitis B Prevents Liver Injury in Patients with Tuberculosis and Hepatitis B Coinfection. Clin Infect Dis. 2020;70(4):660–666. doi:10.1093/cid/ciz241.
   PubMed Web of Science ®Google Scholar
• Kempker RR, Alghamdi WA, Al-Shaer MH, Burch G, Peloquin CA. A Pharmacology Perspective of Simultaneous Tuberculosis and Hepatitis C Treatment. Antimicrob Agents Chemother. 2019;63(12):1–14. doi:10.1128/AAC.01215-19.
   Web of Science ®Google Scholar
• Zenner D, Kruijshaar ME, Andrews N, Abubakar I. Risk of tuberculosis in pregnancy: a national, primary care-based cohort and self-controlled case series study. Am J Respir Crit Care Med. 2012;185(7):779–784. doi:10.1164/rccm.201106-1083OC.
   PubMed Web of Science ®Google Scholar
• Singh N, Perfect JR. Immune reconstitution syndrome and exacerbation of infections after pregnancy. Clin Infect Dis. 2007;45(9):1192–1199. doi:10.1086/522182.
   PubMed Web of Science ®Google Scholar
• Jonsson J, Kuhlmann-Berenzon S, Berggren I, Bruchfeld J. Increased risk of active tuberculosis during pregnancy and post- partum: a register-based cohort study in Sweden. Eur Respir J. 2020;55(3):1901886. doi:10.1183/13993003.01886-2019.
   PubMed Web of Science ®Google Scholar
• Llewelyn M, Cropley I, Wilkinson RJ, Davidson RN. Tuberculosis diagnosed during pregnancy: a prospective study from London. Thorax. 2000;55(2):129–132. doi:10.1136/thorax.55.2.129.
   PubMed Web of Science ®Google Scholar
• Miele K, Bamrah Morris S, Tepper NK. Tuberculosis in Pregnancy. Obstet Gynecol. 2020;135(6):1444–1453. doi:10.1097/AOG.0000000000003890.
   PubMed Web of Science ®Google Scholar
• Jana N, Vasishta K, Jindal SK, Khunnu B, Ghosh K. Perinatal outcome in pregnancies complicated by pulmonary tuberculosis. Int J Gynaecol Obstet. 1994;44(2):119–124. doi:10.1016/0020-7292(94)90064-7.
   PubMed Web of Science ®Google Scholar
• Figueroa-Damian R, Arredondo-Garcia JL. Neonatal outcome of children born to women with tuberculosis. Arch Med Res. 2001;32(1):66–69. doi:10.1016/s0188-4409(00)00266-6.
   PubMed Web of Science ®Google Scholar
• Sobhy S, Babiker Z, Zamora J, Khan KS, Kunst H. Maternal and perinatal mortality and morbidity associated with tuberculosis during pregnancy and the postpartum period: a systematic review and meta-analysis. BJOG. 2017;124(5):727–733. doi:10.1111/1471-0528.14408.
   PubMed Web of Science ®Google Scholar
• Snow KJ, Bekker A, Huang GK, Graham SM. Tuberculosis in pregnant women and neonates: A meta-review of current evidence. Paediatr Respir Rev. 2020;36:27–32. doi:10.1016/j.prrv.2020.02.001.
   PubMed Web of Science ®Google Scholar
• Gupta A, Hughes MD, Garcia-Prats AJ, McIntire K, Hesseling AC. Inclusion of key populations in clinical trials of new anti- tuberculosis treatments: Current barriers and recommendations for pregnant and lactating women, children, and HIV-infected persons. PLoS Med. 2019;16(8):e1002882. doi:10.1371/journal.pmed.1002882.
   PubMed Web of Science ®Google Scholar
• Snider D. Pregnancy and Tuberculosis. Chest. 1984;86(3 Suppl):10S–13S. doi:10.1378/chest.86.3.10S.
   PubMedGoogle Scholar
• Water BJVD, Brooks MB, Huang C-c, et al. Tuberculosis clinical presentation and treatment outcomes in pregnancy: a prospective cohort study. BMC Infect Dis. 2020;20(1):686. doi:10.1186/s12879-020-05416-6.
   PubMed Web of Science ®Google Scholar
• Abdelwahab MT, Leisegang R, Dooley KE, et al. Population Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Pregnant South African Women with Tuberculosis and HIV. Antimicrob Agents Chemother. 2020;64(3):e01978–19. doi:10.1128/AAC.01978-19.
   PubMed Web of Science ®Google Scholar
• Gupta A, Montepiedra G, Aaron L , IMPAACT P1078 TB APPRISE Study Team, et al. Isoniazid Preventive Therapy in HIV-Infected Pregnant and Postpartum Women. N Engl J Med. 2019;381(14):1333–1346. doi:10.1056/nejmoa1813060.
   PubMed Web of Science ®Google Scholar
• Czeizel AE, Rockenbauer M, Olsen J, Sørensen HT. A population-based case-control study of the safety of oral anti-tuberculosis drug treatment during pregnancy. Int J Tuberc Lung Dis. 2001;5(6):564–568.
   PubMed Web of Science ®Google Scholar
• Bothamley G. Drug treatment for tuberculosis during pregnancy: safety considerations. Drug Saf. 2001;24(7):553–565. doi:10.2165/00002018-200124070-00006.
   PubMed Web of Science ®Google Scholar
• World Health Organization & World Health Organization. (2010). Treatment of tuberculosis: guidelines. 4th ed.. World Health Organization.
   Google Scholar
• Yefet E, Schwartz N, Chazan B, Salim R, Romano S, Nachum Z. The safety of quinolones and fluoroquinolones in pregnancy: a meta-analysis. BJOG: Int J Obstet Gy. 2018; 125(9):1069–1076. doi:10.1111/1471-0528.15119.
   PubMed Web of Science ®Google Scholar
• Pediatrics AAo. Red Book: 2018 Report of the Committee on Infectious Diseases. 31st ed. Itasca, Illinois: American Academy of Pediatrics; 2018.
   Google Scholar
• Gallant V, Duvvuri V, McGuire M. Tuberculosis in Canada - Summary 2015. Can Commun Dis Rep. 2017;43(3-4):77–82. doi:10.14745/ccdr.v43i34a04.
   PubMedGoogle Scholar
• Hochberg NS, Horsburgh CR.Jr. Prevention of tuberculosis in older adults in the United States: obstacles and opportunities. Clin Infect Dis. 2013;56(9):1240–1247. May doi:10.1093/cid/cit027.
   PubMed Web of Science ®Google Scholar
• Symes MJ, Probyn B, Daneshvar C, Telisinghe L. Diagnosing Pulmonary Tuberculosis in the Elderly. Curr Geri Rep. 2020;9(2):30–39. doi:10.1007/s13670-020-00319-5.
   Web of Science ®Google Scholar
• Gardner Toren K, Spitters C, Pecha M, Bhattarai S, Horne DJ, Narita M. Tuberculosis in Older Adults: Seattle and King County, Washington. Clin Infect Dis. 2020;70(6):1202–1207 doi:10.1093/cid/ciz306.
   PubMed Web of Science ®Google Scholar
• Hase I, Toren KG, Hirano H, et al. Pulmonary Tuberculosis in Older Adults: Increased Mortality Related to Tuberculosis Within Two Months of Treatment Initiation. Drugs and Aging. 2021;38(9):807–815. doi:10.1007/s40266-021-00880-4.
   PubMed Web of Science ®Google Scholar
• Kwon BS, Kim Y, Lee SH, et al. The high incidence of severe adverse events due to pyrazinamide in elderly patients with tuberculosis. PLoS One. 2020;15(7):e0236109–10. doi:10.1371/journal.pone.0236109.
   Web of Science ®Google Scholar
• Marra F, Marra CA, Bruchet N, et al. Adverse drug reactions associated with first-line anti-tuberculosis drug regimens. Int J Tuberc Lung Dis. 2007;11(8):868–875.
   PubMed Web of Science ®Google Scholar
• Tweed CD, Wills GH, Crook AM, et al. Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study. BMC Med. 2018;16(1):46. doi:10.1186/s12916-018-1033-7.
   PubMedGoogle Scholar
• Hosford JD, von Fricken ME, Lauzardo M, et al. Hepatotoxicity from antituberculous therapy in the elderly: a systematic review. Tuberculosis (Edinb). 2015;95(2):112–122. doi:10.1016/j.tube.2014.10.006.
   PubMed Web of Science ®Google Scholar
• Lonnroth K, Williams BG, Stadlin S, Jaramillo E, Dye C. Alcohol use as a risk factor for tuberculosis – a systematic review. BMC Public Health. 2008;8(1):289. doi:10.1186/1471-2458-8-289.
   PubMed Web of Science ®Google Scholar
• Imtiaz S, Shield KD, Roerecke M, Samokhvalov AV, Lönnroth K, Rehm J. Alcohol consumption as a risk factor for tuberculosis: Meta-analyses and burden of disease. Eur Respir J. 2017;50(1):1700216. doi:10.1183/13993003.00216-2017.
   PubMed Web of Science ®Google Scholar
• Rehm J, Samokhvalov AV, Neuman MG, et al. The association between alcohol use, alcohol use disorders and tuberculosis (TB). A systematic review. BMC Public Health. 2009;9(1):412–450. doi:10.1186/1471-2458-9-450.
   PubMedGoogle Scholar
• Storla DG, Yimer S, Bjune GA. A systematic review of delay in the diagnosis and treatment of tuberculosis. BMC Public Health. 2008;8(1):15–19. doi:10.1186/1471-2458-8-15.
   PubMed Web of Science ®Google Scholar
• Volkmann T, Moonan PK, Miramontes R, Oeltmann JE. Tuberculosis and excess alcohol use in the United States, 1997-2012. Int J Tuberc Lung Dis. 2015;19(1):111–119. doi:10.5588/ijtld.14.0516.
   PubMed Web of Science ®Google Scholar
• Ragan EJ, Kleinman MB, Sweigart B, et al. The impact of alcohol use on tuberculosis treatment outcomes: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2020;24(1):73–82. doi:10.5588/ijtld.19.0080.
   PubMed Web of Science ®Google Scholar
• Samuels JP, Sood A, Campbell JR, Ahmad Khan F, Johnston JC. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. Sci Rep. 2018;8(1):1–13. doi:10.1038/s41598-018-23344-z.
   PubMedGoogle Scholar
• Torres NMC, Rodríguez JJQ, Andrade PSP, Arriaga MB, Netto EM. Factors predictive of the success of tuberculosis treatment: A systematic review with meta-analysis. PLoS One. 2019;14(12):e0226507–24. doi:10.1371/journal.pone.0226507.
   Web of Science ®Google Scholar
• Burman WJ, Cohn DL, Rietmeijer CA, Judson FN, Sbarbaro JA, Reves RR. Noncompliance with directly observed therapy for tuberculosis: Epidemiology and effect on the outcome of treatment. Chest. 1997;111(5):1168–1173. doi:10.1378/chest.111.5.1168.
   PubMed Web of Science ®Google Scholar
• Deiss RG, Rodwell TC, Garfein RS. Tuberculosis and illicit drug use: Review and update. Clin Infect Dis. 2009;48(1):72–82. doi:10.1086/594126.
   PubMed Web of Science ®Google Scholar
• Minja LT, Hella J, Mbwambo J, et al. High burden of tuberculosis infection and disease among people receiving medication-assisted treatment for substance use disorder in Tanzania. PLoS One. 2021;16(4):e0250038. doi:10.1371/journal.pone.0250038.
   PubMed Web of Science ®Google Scholar
• Getahun H, Gunneberg C, Sculier D, Verster A, Raviglione M. Tuberculosis and HIV in people who inject drugs: Evidence for action for tuberculosis, HIV, prison and harm reduction services. Curr Opin HIV Aids. 2012;7(4):345–353. doi:10.1097/COH.0b013e328354bd44.
   PubMed Web of Science ®Google Scholar
• Duarte R, Lönnroth K, Carvalho C, et al. Tuberculosis, social determinants and co-morbidities (including HIV). Pulmonology. 2018;24(2):115–119. doi:10.1016/j.rppnen.2017.11.003.
   PubMed Web of Science ®Google Scholar
• Pablos-Méndez A, Knirsch CA, Barr RG, Lerner BH, Frieden TR. Nonadherence in tuberculosis treatment: Predictors and consequences in New York City. American Journal of Medicine. 1997;102(2):164–170. doi:10.1016/S0002-9343(96)00402-0.
   PubMed Web of Science ®Google Scholar
• Chaisson RE, Barnes GL, Hackman J, et al. A randomized, controlled trial of interventions to improve adherence to isoniazid therapy to prevent tuberculosis in injection drug users. American Journal of Medicine. 2001;110(8):610–615. doi:10.1016/S0002-9343(01)00695-7.
   PubMed Web of Science ®Google Scholar
• Batki SL, Gruber VA, Bradley JM, Bradley M, Delucchi K. A controlled trial of methadone treatment combined with directly observed isoniazid for tuberculosis prevention in injection drug users. Drug Alcohol Depend. 2002;66(3):283–293. doi:10.1016/S0376-8716(01)00208-3.
   PubMed Web of Science ®Google Scholar
• Smirnoff M, Goldberg R, Indyk L, Adler JJ. Directly observed therapy in an inner city hospital. International Journal of Tuberculosis and Lung Disease. 1998;2(2):134–139.
   PubMed Web of Science ®Google Scholar
• Schluger N, Ciotoli C, Cohen D, Johnson H, Rom WN. Comprehensive tuberculosis control for patients at high risk for noncompliance. Am J Respir Crit Care Med. 1995;151(5):1486–1490. doi:10.1164/ajrccm.151.5.7735604.
   PubMed Web of Science ®Google Scholar
• Raistrick D, Hay A, Wolff K. Methadone maintenance and tuberculosis treatment. BMJ. 1996;313(7062):925–926. doi:10.1136/bmj.313.7062.925.
   PubMedGoogle Scholar
• McCance-Katz EF, Moody DE, Prathikanti S, Friedland G, Rainey PM. Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients. Drug Alcohol Depend. 2011;118(2-3):326–334. doi:10.1016/j.drugalcdep.2011.04.013.
   PubMed Web of Science ®Google Scholar
• Brown LS, Sawyer RC, Li R, Cobb MN, Colborn DC, Narang PK. Lack of a pharmacologic interaction between rifabutin and methadone in HIV-infected former injecting drug users. Drug Alcohol Depend. 1996;43(1-2):71–77. doi:10.1016/S0376-8716(97)84352-9.
   PubMed Web of Science ®Google Scholar
• Bates MN, Khalakdina A, Pai M, Chang L, Lessa F, Smith KR. Risk of tuberculosis from exposure to tobacco smoke: A systematic review and meta-analysis. Arch Intern Med. 2007;167(4):335–342. doi:10.1001/archinte.167.4.335.
   PubMedGoogle Scholar
• Van Zyl Smit RN, Pai M, Yew WW, et al. Global lung health: The colliding epidemics of tuberculosis, tobacco smoking, HIV and COPD. Eur Respir J. 2010;35(1):27–33. doi:10.1183/09031936.00072909.
   PubMed Web of Science ®Google Scholar
• Obore N, Kawuki J, Guan J, Papabathini SS, Wang L. Association between indoor air pollution, tobacco smoke and tuberculosis: an updated systematic review and meta-analysis. Public Health. 2020;187:24–35. doi:10.1016/j.puhe.2020.07.031.
   PubMed Web of Science ®Google Scholar
• Altet-Gómez MN, Alcaide J, Godoy P, Romero MA. Hernández Del Rey I. Clinical and epidemiological aspects of smoking and tuberculosis: A study of 13 038 cases. International Journal of Tuberculosis and Lung Disease. 2005;9(4):430–436.
   PubMed Web of Science ®Google Scholar
• Leung CC, Yew WW, Chan CK, et al. Smoking adversely affects treatment response, outcome and relapse in tuberculosis. Eur Respir J. 2015;45(3):738–745. doi:10.1183/09031936.00114214.
   PubMed Web of Science ®Google Scholar
• Burusie A, Enquesilassie F, Addissie A, Dessalegn B, Lamaro T. Effect of smoking on tuberculosis treatment outcomes: A systematic review and meta-analysis. PLoS One. 2020;15(9):e0239333–20. doi:10.1371/journal.pone.0239333.
   Web of Science ®Google Scholar
• Gajalakshmi V, Peto R, Kanaka TS, Jha P. Smoking and mortality from tuberculosis and other diseases in India: Retrospective study of 43 000 adult male deaths and 35 000 controls. Lancet. 2003;362(9383):507–515. doi:10.1016/S0140-6736(03)14109-8.
   PubMed Web of Science ®Google Scholar
• Yen YF, Yen MY, Lin YS, et al. Smoking increases risk of recur- rence after successful anti-tuberculosis treatment: A population-based study. Int J Tuberc Lung Dis. 2014;18(4):492–498. doi:10.5588/ijtld.13.0694.
   PubMed Web of Science ®Google Scholar
• Whitehouse E, Lai J, Golub JE, Farley JE. A systematic review of the effectiveness of smoking cessation interventions among patients with tuberculosis. Public Health Action. 2018;8(2):37–49. doi:10.5588/pha.18.0006.
   PubMed Web of Science ®Google Scholar
• Jeyashree K, Kathirvel S, Shewade HD, Kaur H, Goel S, Cochrane Tobacco Addiction Group. Smoking cessation interventions for pulmonary tuberculosis treatment outcomes. The Cochrane Database of Systematic Reviews. 2016;CD011125. doi:10.1002/14651858.CD011125.pub2.
   PubMed Web of Science ®Google Scholar
• Alffenaar JWC, Gumbo T, Dooley KE, et al. Integrating pharmacokinetics and pharmacodynamics in operational research to end tuberculosis. Clin Infect Dis. 2020;70(8):1774–1780. doi:10.1093/cid/ciz942.
   PubMed Web of Science ®Google Scholar
• Hall RG, Leff RD, Gumbo T. Treatment of active pulmonary tuberculosis in adults: Current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2009;29(12):1468–1481. doi:10.1592/phco.29.12.1468.
   PubMed Web of Science ®Google Scholar
• Abrogoua DP, Kamenan BAT, Ahui BJM, Doffou E. Pharmaceutical interventions in the management of tuberculosis in a pneumoph- tisiology department, ivory coast. Ther Clin Risk Manag. 2016;12:1749–1756. doi:10.2147/TCRM.S118442.
   PubMedGoogle Scholar
• Reitman ML, Chu X, Cai X, et al. Rifampin’s acute inhibitory and chronic inductive drug interactions: Experimental and model-based approaches to drug-drug interaction trial design. Clin Pharmacol Ther. 2011;89(2):234–242. doi:10.1038/clpt.2010.271.
   PubMed Web of Science ®Google Scholar
• Sekaggya-Wiltshire C, Dooley KE. Pharmacokinetic and pharmacodynamic considerations of rifamycin antibiotics for the treatment of tuberculosis. Expert Opin Drug Metab Toxicol. 2019;15(8):615–618. doi:10.1080/17425255.2019.1648432.
   PubMed Web of Science ®Google Scholar
• Dooley KE, Bliven-Sizemore EE, Weiner M, et al. Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers. Clin Pharmacol Ther. 2012;91(5):881–888. doi:10.1038/clpt.2011.323.
   PubMed Web of Science ®Google Scholar
• Sahasrabudhe V, Zhu T, Vaz A, Tse S. Drug Metabolism and Drug Interactions: Potential Application to Antituberculosis Drugs. J Infect Dis. 2015;211(suppl 3):S107–S114. doi:10.1093/infdis/jiv009.
   PubMedGoogle Scholar
• McFeely SJ, Yu J, Zhao P, et al. Drug-Drug Interactions of Infectious Disease Treatments in Low-Income Countries: A Neglected Topic? Clin Pharmacol Ther. 2019;105(6):1378–1385. doi:10.1002/cpt.1397.
   PubMed Web of Science ®Google Scholar
• Yang CS, Boswell R, Bungard TJ. A case series of the rifampin-warfarin drug interaction: focus on practical warfarin management. Eur J Clin Pharmacol. 2021;77(3):341–348. doi:10.1007/s00228-020-03057-x.
   PubMed Web of Science ®Google Scholar
• Martins MAP, Reis AMM, Sales MF, et al. Rifampicin-warfarin interaction leading to macroscopic hematuria: A case report and review of the literature. BMC Pharmacol Toxicol. 2013;14(1):10–27. doi:10.1186/2050-6511-14-27.
   PubMedGoogle Scholar
• Wiggins BS, Dixon DL, Neyens RR, Page RL, Gluckman TJ. Select Drug-Drug Interactions With Direct Oral Anticoagulants: JACC Review Topic of the Week. J Am Coll Cardiol. 2020;75(11):1341–1350. doi:10.1016/j.jacc.2019.12.068.
   PubMed Web of Science ®Google Scholar
• Lutz JD, Kirby BJ, Wang L, et al. Cytochrome P450 3A Induction Predicts P-glycoprotein Induction; Part 2: Prediction of Decreased Substrate Exposure After Rifabutin or Carbamazepine. Clin Pharmacol Ther. 2018;104(6):1191–1198. doi:10.1002/cpt.1072.
   PubMed Web of Science ®Google Scholar
• Chang SH, Chou IJ, Yeh YH, et al. Association between use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation. JAMA – Journal of the American Medical Association. 2017;318(13):1250–1259. doi:10.1001/jama.2017.13883.
   PubMed Web of Science ®Google Scholar
• Mendell J, Chen S, He L, Desai M, Parasramupria DA. The effect of rifampin on the pharmacokinetics of edoxaban in healthy adults. Clin Drug Investig. 2015;35(7):447–453. doi:10.1007/s40261-015-0298-2.
   PubMed Web of Science ®Google Scholar
• Vakkalagadda B, Frost C, Byon W, et al. Effect of rifampin on the pharmacokinetics of apixaban, an oral direct inhibitor of factor xa. Am J Cardiovasc Drugs. 2016;16(2):119–127. doi:10.1007/s40256-015-0157-9.
   PubMed Web of Science ®Google Scholar
• Kay L, Kampmann J, Svendsen T, et al. Influence of rifampicin and isoniazid on the kinetics of phenytoin. Br J Clin Pharmacol. 1985;20(4):323–326. doi:10.1111/j.1365-2125.1985.tb05071.x.
   PubMed Web of Science ®Google Scholar
• Ebert U, Thong NQ, Oertel R, Kirch W. Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. European Journal of Clinical Pharmacology. 2000;56(4):299–304. doi:10.1007/s002280000146.
   PubMed Web of Science ®Google Scholar
• Wimpelmann J, Høvik H, Riedel B, Slørdal L. The interaction between rifampicin and lamotrigine: A case report. Br J Clin Pharmacol. 2019;85(8):1859–1860. doi:10.1111/bcp.13973.
   PubMed Web of Science ®Google Scholar
• Egelund EF, Mohamed MEF, Fennelly KP, Peloquin CA. Concomitant use of carbamazepine and rifampin in a patient with mycobacterium avium complex and seizure disorder. J Pharm Technol. 2014;30(3):93–96. doi:10.1177/8755122514523934.
   PubMedGoogle Scholar
• Niemi M, Backman JT, Neuvonen M, Neuvonen PJ. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects. Br J Clin Pharmacol. 2003;56(4):427–432. doi:10.1046/j.1365-2125.2003.01884.x.
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Neuvonen M, Neuvonen PJ, Kivistö KT. Effects of rifampin on the pharmacokinetics and phar- macodynamics of glyburide and glipizide. Clinical Pharmacology and Therapeutics. 2001;69(6):400–406. doi:10.1067/mcp.2001.115822.
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Neuvonen PJ. Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. Clinical Pharmacology and Therapeutics. 2004;76(3):239–249. doi:10.1016/j.clpt.2004.05.001.
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivistö KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet. 2003;42(9):819–850. doi:10.2165/00003088-200342090-00003.
   PubMed Web of Science ®Google Scholar
• Park JY, Kim KA, Kang MH, Kim SL, Shin JG. Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. Clin Pharmacol Ther. 2004;75(3):157–162. doi:10.1016/j.clpt.2003.10.003.
   PubMed Web of Science ®Google Scholar
• Sahi J, Black CB, Hamilton GA, et al. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos. 2003;31(4):439–446. doi:10.1124/dmd.31.4.439.
   PubMed Web of Science ®Google Scholar
• Jaakkola T, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ. Effect of rifampicin on the pharmacokinetics of pioglitazone. Br J Clin Pharmacol. 2006;61(1):70–78. doi:10.1111/j.1365-2125.2005.02515.x.
   PubMed Web of Science ®Google Scholar
• Riza AL, Pearson F, Ugarte-Gil C, et al. Clinical management of concurrent diabetes and tuberculosis and the implications for patient services. Lancet Diabetes Endocrinol. 2014;2(9):740–753. doi:10.1016/S2213-8587(14)70110-X.
   PubMed Web of Science ®Google Scholar
• Tucker RM, Denning DW, Hanson LH, et al. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis. 1992;14(1):165–174. doi:10.1093/clinids/14.1.165.
   PubMed Web of Science ®Google Scholar
• Hohmann C, Kang EM, Jancel T. Rifampin and posaconazole coadministration leads to decreased serum posaconazole concentrations. Clin Infect Dis. 2010;50(6):939–940. doi:10.1086/650740.
   PubMed Web of Science ®Google Scholar
• Geist MJ, Egerer G, Burhenne J, Riedel KD, Mikus G. Induction of voriconazole metabolism by rifampin in a patient with acute myeloid leukemia: importance of interdisciplinary communication to prevent treatment errors with complex medications. Antimicrob Agents Chemother. 2007;51(9):3455–3456. doi:10.1128/AAC.00579-07.
   PubMed Web of Science ®Google Scholar
• Townsend R, Dietz A, Hale C, et al. Pharmacokinetic Evaluation of CYP3A4-Mediated Drug-Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy Adults. Clin Pharmacol Drug Dev. 2017;6(1):44–53. doi:10.1002/cpdd.285.
   PubMed Web of Science ®Google Scholar
• Ayudhya DPN, Thanompuangseree N, Tansuphaswadikul S. Effect of rifampicin on the pharmacokinetics of fluconazole in patients with AIDS. Clin Pharmacokinet. 2004;43(11):725–732. doi:10.2165/00003088-200443110-00003.
   PubMed Web of Science ®Google Scholar
• Kirch W, Rose I, Klingmann I, Pabst J, Ohnhaus EE. Interaction of bisoprolol with cimetidine and rifampicin. Eur J Clin Pharmacol. 1986;31(1):59–62. doi:10.1007/BF00870987.
   PubMed Web of Science ®Google Scholar
• Tada Y, Tsuda Y, Otsuka T, et al. Case report: Nifedipine-rifampicin interaction attenuates the effect on blood pressure in a patient with essential hypertension. Am J Med Sci. 1992;303(1):25–27. doi:10.1097/00000441-199201000-00006.
   PubMed Web of Science ®Google Scholar
• Williamson KM, Patterson JH, McQueen RH, Adams KF, Pieper JA. Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. Clin Pharmacol Ther. 1998;63(3):316–323. doi:10.1016/S0009-9236(98)90163-1.
   PubMed Web of Science ®Google Scholar
• Liu W, Yan T, Chen K, Yang L, Benet LZ, Zhai S. Predicting Interactions between Rifampin and Antihypertensive Drugs Using the Biopharmaceutics Drug Disposition Classification System. Pharmacotherapy. 2020;40(4):274–290. doi:10.1002/phar.2380.
   PubMed Web of Science ®Google Scholar
• McAllister WA, Thompson PJ, Al-Habet SM, Rogers HJ. Rifampicin reduces effectiveness and bioavailability of prednisolone. Br Med J (Clin Res Ed). 1983;286(6369):923–925. doi:10.1136/bmj.286.6369.923.
   PubMedGoogle Scholar
• Powell-Jackson PR, Gray BJ, Heaton RW, Costello JF, Williams R, English J. Adverse effect of rifampicin administration on steroid-dependent asthma. Am Rev Respir Dis. 1983;128(2):307–310. doi:10.1164/arrd.1983.128.2.307.
   PubMed Web of Science ®Google Scholar
• Lee KH, Shin JG, Chong WS, et al. Time course of the changes in prednisolone pharmacokinetics after co-administration or ­discontinuation of rifampin. Eur J Clin Pharmacol. 1993;45(3):287–289. doi:10.1007/BF00315399.
   PubMed Web of Science ®Google Scholar
• Bhaloo S, Prasad GV. Severe reduction in tacrolimus levels with rifampin despite multiple cytochrome P450 inhibitors: a case report. Transplant Proc. 2003;35(7):2449–2451. doi:10.1016/j.transproceed.2003.08.019.
   PubMed Web of Science ®Google Scholar
• van Buren D, Wideman CA, Ried M, et al. The antagonistic effect of rifampin upon cyclosporine bioavailability. Transplant Proc. 1984;16(6):1642–1645.
   PubMed Web of Science ®Google Scholar
• Hebert MF, Fisher RM, Marsh CL, Dressler D, Bekersky I. Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol. 1999;39(1):91–96. doi:10.1177/00912709922007499.
   PubMed Web of Science ®Google Scholar
• Wang Y-C, Salvador NG, Lin C-C, et al. Comparative analysis of the drug-drug interaction between immunosuppressants, safety and efficacy of rifabutin from rifampicin-based Anti-TB treatment in living donor liver transplant recipients with active tuberculosis. Biomedical Journal. 2020:1–9. doi:10.1016/j.bj.2020.08.010.
   PubMed Web of Science ®Google Scholar
• Strayhorn VA, Baciewicz AM, Self TH. Update on rifampin drug interactions, III. Arch Intern Med. 1997;157(21):2453–2458.
   PubMedGoogle Scholar
• Nolan SR, Self TH, Norwood JM. Interaction between rifampin and levothyroxine. South Med J. 1999;92(5):529–531. doi:10.1097/00007611-199905000-00018.
   PubMed Web of Science ®Google Scholar
• Kim HI, Kim TH, Kim H, et al. Effect of Rifampin on thyroid function test in patients on levothyroxine medication. PLoS One. 2017;12(1):e0169775–11. doi:10.1371/journal.pone.0169775.
   Web of Science ®Google Scholar
• Takasu N, Kinjou Y, Kouki T, Takara M, Ohshiro Y, Komiya I. Rifampin-induced hypothyroidism. J Endocrinol Invest. 2006;29(7):645–649. doi:10.1007/BF03344165.
   PubMed Web of Science ®Google Scholar
• Kreek MJ, Garfield JW, Gutjahr CL, Giusti LM. Rifampin-induced methadone withdrawal. N Engl J Med. 1976;294(20):1104–1106. doi:10.1056/NEJM197605132942008.
   PubMed Web of Science ®Google Scholar
• Badhan RKS, Gittins R, Al Zabit D. The optimization of methadone dosing whilst treating with rifampicin: A pharmacokinetic modeling study. Drug Alcohol Depend. 2019;200:168–180. doi:10.1016/j.drugalcdep.2019.03.013.
   PubMed Web of Science ®Google Scholar
• Simmons KB, Haddad LB, Nanda K, Curtis KM. Drug interactions between rifamycin antibiotics and hormonal contraception: a systematic review. BJOG. 2018;125(7):804–811. doi:10.1111/1471-0528.15027.
   PubMed Web of Science ®Google Scholar